FDA’s top drug regulator ousted amid agency upheaval
Summary
The Food and Drug Administration (FDA) removed Tracey Beth Høeg from her role as acting director of its Center for Drug Evaluation and Research (CDER). This marks the fifth change in leadership for the division since December, highlighting ongoing instability in the agency's top drug regulation team.Key Facts
- Tracey Beth Høeg was the acting director of the FDA’s Center for Drug Evaluation and Research.
- She was removed from her position on a Friday.
- Høeg had held the acting director role since December.
- The CDER has seen five different heads or acting heads since the start of this period.
- The changes reflect ongoing leadership instability within the FDA’s drug evaluation division.
- The FDA is responsible for overseeing the safety and approval of drugs in the United States.
- The leadership changes are occurring during President Donald Trump’s current administration.
- This situation may affect the agency’s work on drug approvals and safety regulations.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
